News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,588 Results
Type
Article (42556)
Company Profile (294)
Press Release (676738)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (210491)
Career Advice (2092)
Deals (36637)
Drug Delivery (107)
Drug Development (83071)
Employer Resources (175)
FDA (16587)
Job Trends (15419)
News (356138)
Policy (33931)
Tag
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (92)
Alliances (51454)
ALS (97)
Alzheimer's disease (1402)
Antibody-drug conjugate (ADC) (140)
Approvals (16583)
Artificial intelligence (277)
Autoimmune disease (24)
Automation (16)
Bankruptcy (371)
Best Places to Work (11771)
BIOSECURE Act (20)
Biosimilars (113)
Biotechnology (188)
Bladder cancer (78)
Brain cancer (29)
Breast cancer (293)
Cancer (2346)
Cardiovascular disease (188)
Career advice (1753)
Career pathing (31)
CAR-T (155)
Cell therapy (440)
Cervical cancer (20)
Clinical research (67629)
Collaboration (877)
Company closure (2)
Compensation (564)
Complete response letters (25)
COVID-19 (2663)
CRISPR (47)
C-suite (257)
Cystic fibrosis (105)
Data (2313)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (279)
Diagnostics (6463)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (115)
Drug shortages (28)
Duchenne muscular dystrophy (97)
Earnings (88694)
Editorial (41)
Employer branding (21)
Employer resources (149)
Events (115507)
Executive appointments (753)
FDA (17973)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (775)
Gene editing (116)
Generative AI (21)
Gene therapy (325)
GLP-1 (757)
Government (4550)
Grass and pollen (5)
Guidances (150)
Healthcare (19002)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (132)
Indications (30)
Infectious disease (2808)
Inflammatory bowel disease (148)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (99)
Interviews (323)
IPO (16800)
IRA (47)
Job creations (4061)
Job search strategy (1492)
Kidney cancer (10)
Labor market (43)
Layoffs (500)
Leadership (18)
Legal (8381)
Liver cancer (77)
Lung cancer (326)
Lymphoma (158)
Machine learning (9)
Management (59)
Manufacturing (338)
MASH (75)
Medical device (13470)
Medtech (13475)
Mergers & acquisitions (20401)
Metabolic disorders (726)
Multiple sclerosis (82)
NASH (17)
Neurodegenerative disease (96)
Neuropsychiatric disorders (29)
Neuroscience (1971)
NextGen: Class of 2025 (6638)
Non-profit (4528)
Now hiring (40)
Obesity (386)
Opinion (232)
Ovarian cancer (81)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (152)
Partnered (21)
Patents (247)
Patient recruitment (116)
Peanut (49)
People (59324)
Pharmaceutical (91)
Pharmacy benefit managers (20)
Phase I (20973)
Phase II (29761)
Phase III (22296)
Pipeline (1358)
Policy (159)
Postmarket research (2655)
Preclinical (8941)
Press Release (68)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (402)
Real estate (6258)
Recruiting (67)
Regulatory (23188)
Reports (47)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (134)
Series B (88)
Service/supplier (12)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3730)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (52)
The Weekly (50)
Vaccines (718)
Venture capitalists (42)
Weight loss (255)
Women's health (36)
Worklife (16)
Date
Last 7 days (940)
Last 30 days (2974)
Last 365 days (32849)
2025 (11862)
2024 (35773)
2023 (40632)
2022 (51799)
2021 (56334)
2020 (54791)
2019 (47400)
2018 (35775)
2017 (33141)
2016 (32667)
2015 (38620)
2014 (32518)
2013 (27634)
2012 (29732)
2011 (30489)
2010 (28502)
Location
Africa (782)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40776)
Australia (6528)
California (6405)
Canada (2074)
China (549)
Colorado (274)
Connecticut (279)
Delaware (159)
Europe (87111)
Florida (950)
Georgia (212)
Idaho (57)
Illinois (559)
India (26)
Indiana (327)
Iowa (11)
Japan (175)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (927)
Massachusetts (4796)
Michigan (225)
Minnesota (403)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1800)
New Mexico (29)
New York (1806)
North Carolina (1006)
North Dakota (8)
Northern California (2812)
Ohio (208)
Oklahoma (14)
Oregon (39)
Pennsylvania (1428)
Puerto Rico (13)
Rhode Island (33)
South America (1164)
South Carolina (25)
South Dakota (1)
Southern California (2411)
Tennessee (105)
Texas (954)
United States (24106)
Utah (190)
Virginia (160)
Washington D.C. (64)
Washington State (570)
West Virginia (3)
Wisconsin (59)
719,588 Results for "teva pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
March 31, 2025
·
20 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Press Releases
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
May 7, 2025
·
2 min read
Press Releases
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
May 5, 2025
·
22 min read
Policy
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
UroGen Pharma Ltd. today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 (“the ’074 patent”) and 9,950,069.
April 3, 2024
·
9 min read
Earnings
Teva Reports Strong Generics Demand in Q3, Expects Higher 2024 Revenue
Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.
November 7, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
June 24, 2024
·
9 min read
Press Releases
Teva Releases Q1 2025 Aide Memoire
March 28, 2025
·
2 min read
Legal
Teva to Pay $450M in Settlement With DOJ Over Kickback and Price-Fixing Allegations
The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred prosecution agreement.
October 11, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
April 7, 2025
·
8 min read
1 of 71,959
Next
